NCT05049122View on ClinicalTrials.gov

Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 22, 2021

Primary Completion Date

December 21, 2022

Study Completion Date

July 5, 2023

Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
DRUG

Dupilumab SAR231893

Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)

Trial Locations (1)

Unknown

Investigational site JAPAN, Japan

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY